Back to Menu
1. Chemotherapy
The main treatment modality. Regimens vary by subtype and are often combined with targeted agents as chemoimmunotherapy to improve efficacy.
2. Radiotherapy
Used for curative treatment in early-stage disease or palliation in advanced disease; precision targeting helps protect normal tissues.
3. Targeted therapy
Includes agents such as anti-CD20 monoclonal antibodies and BTK inhibitors, which specifically block tumor-related signaling pathways with relatively lower toxicity.
4. Immunotherapy
Agents such as PD-1 inhibitors activate the immune system to attack tumor cells and have shown substantial efficacy in recent years.
5. CAR-T cell therapy
Patient T cells are genetically engineered to precisely target lymphoma cells; this approach has shown outstanding efficacy in relapsed or refractory large B-cell lymphoma.
6. Surgery
Primarily used for diagnostic biopsy; a small number of localized extranodal lesions may be amenable to surgical resection.
7. Antibody-drug conjugates
Antibodies deliver cytotoxic agents directly to tumor cells, enabling highly effective and lower-toxicity “precision targeting.”
8. Hematopoietic stem cell transplantation
Autologous or allogeneic transplantation may be used in high-risk, relapsed, or refractory patients to restore hematopoiesis after intensive therapy.
9. Supportive care
Transfusion support, anti-infective treatment, and nutritional support are provided throughout the disease course to improve treatment tolerance and quality of life.
10. Minimally invasive treatment
Interventional procedures or radiofrequency ablation may be used with limited trauma and faster recovery, mainly for palliation or in combination treatment in selected cases.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that lymphoma is a heterogeneous malignant disease with complex treatment needs and significant health impact. Early diagnosis and standardized treatment are key to improving cure rates. Multidisciplinary comprehensive care, together with newer approaches such as CAR-T therapy, targeted therapy, and immunotherapy, continues to improve prognosis. The public should improve awareness, undergo regular health examinations, and seek medical attention promptly when symptoms occur.
1. Chemotherapy
The main treatment modality. Regimens vary by subtype and are often combined with targeted agents as chemoimmunotherapy to improve efficacy.
2. Radiotherapy
Used for curative treatment in early-stage disease or palliation in advanced disease; precision targeting helps protect normal tissues.
3. Targeted therapy
Includes agents such as anti-CD20 monoclonal antibodies and BTK inhibitors, which specifically block tumor-related signaling pathways with relatively lower toxicity.
4. Immunotherapy
Agents such as PD-1 inhibitors activate the immune system to attack tumor cells and have shown substantial efficacy in recent years.
5. CAR-T cell therapy
Patient T cells are genetically engineered to precisely target lymphoma cells; this approach has shown outstanding efficacy in relapsed or refractory large B-cell lymphoma.
6. Surgery
Primarily used for diagnostic biopsy; a small number of localized extranodal lesions may be amenable to surgical resection.
7. Antibody-drug conjugates
Antibodies deliver cytotoxic agents directly to tumor cells, enabling highly effective and lower-toxicity “precision targeting.”
8. Hematopoietic stem cell transplantation
Autologous or allogeneic transplantation may be used in high-risk, relapsed, or refractory patients to restore hematopoiesis after intensive therapy.
9. Supportive care
Transfusion support, anti-infective treatment, and nutritional support are provided throughout the disease course to improve treatment tolerance and quality of life.
10. Minimally invasive treatment
Interventional procedures or radiofrequency ablation may be used with limited trauma and faster recovery, mainly for palliation or in combination treatment in selected cases.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that lymphoma is a heterogeneous malignant disease with complex treatment needs and significant health impact. Early diagnosis and standardized treatment are key to improving cure rates. Multidisciplinary comprehensive care, together with newer approaches such as CAR-T therapy, targeted therapy, and immunotherapy, continues to improve prognosis. The public should improve awareness, undergo regular health examinations, and seek medical attention promptly when symptoms occur.